Which companies are Shanghai Obio Technology (Group)'s closest peers?

The cockpit's peer set: Shattuck Labs (STTK), Komipharm International (041960.KS), Eupraxia Pharmaceuticals (EPRX.TO), Steminent Biotherapeutics (7729.TWO), Medigen Vaccine Biologics (6547.TWO), Jacobio Pharmaceuticals (1167.HK), Shanghai ZJ Bio-Tech (688317.SS), Hanx Biopharmaceuticals (Wuhan) (3378.HK).

Is Shanghai Obio Technology (Group) expensive compared with its peers?

On ev / sales it trades at 11.4× against a peer median of 10.7×, 8th most expensive of 16 in its peer set.

How has Shanghai Obio Technology (Group) stock performed?

Over six months to 6 Nov 2026 the shares returned -4.4% against -7.3% for the median peer; over one year -13.3%.

← CockpitCompetitor Analysis › 688238.SS Shanghai Obio Technology (Group) Corp., Ltd. Class AOpen in the cockpit ↗

Shanghai Obio Technology (Group) Corp., Ltd. Class A688238.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Momentum leader 80

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$462M

US dollars, full cap

Free float

100%

of shares outstanding

$/day

$32.8M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

-16.9 pp

WACC 9.5%

Hurdle

n/a

no reverse DCF

Next earnings

161 days

16 Apr 2027

Close · CNYCN¥6.49

1D-3.4%

1W+3.8%

1M-21.4%

3M+15.9%

6M-4.4%

YTD-2.5%

1Y-13.3%

ATR %8.4%

52w lowhigh30.4% off high

What Shanghai Obio Technology (Group) does

Employees: 715

Shanghai Obio Technology (Group) at a glance

Size Shanghai Obio Technology (Group) (688238.SS) is a China Health Care company (Biotechnology) with a market value of $462M, the 4056th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥6.49 on 6 Nov 2026.

Performance Over six months the shares fell 4.4%, against -7.3% for the median peer and -16.4% for the China market (cap-weighted) — 8th highest of 20 in its peer set.

Growth Revenue grew 20.1% over the last twelve months (peer median +3.6%); the operating margin is -78.9% (peer median -9.8%).

Valuation It trades at 11.4× enterprise value to sales against a peer median of 10.7× (8th most expensive of 16).

Capital Return on invested capital runs 16.9 points below its cost of capital (9.5% WACC).

Next results Next results expected around 16 Apr 2027 (exchange calendar; dates can move).

Relative performance

Six months, rebased to 100: Shanghai Obio Technology (Group) against the median of its 20 peers (local-currency closes).

Shanghai Obio Technology (Group) financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	CN¥294M	CN¥260M	CN¥248M	CN¥205M	CN¥291M
Revenue growth	—	+5%	+21%	-30%	—
Gross profit	CN¥39.9M	-CN¥74.8M	-CN¥118M	-CN¥22.1M	CN¥125M
EBITDA	n/a	-CN¥125M	-CN¥226M	-CN¥139M	CN¥40.9M
Net income	-CN¥219M	-CN¥235M	-CN¥322M	-CN¥128M	CN¥39.3M
Free cash flow	-CN¥169M	-CN¥227M	-CN¥228M	-CN¥636M	-CN¥460M
Capital expenditure	CN¥91.8M	CN¥126M	CN¥167M	CN¥547M	CN¥484M
Total debt	CN¥822M	CN¥420M	CN¥216M	CN¥191M	CN¥92.0M

Quarterly statements and history in the cockpit →

Shanghai Obio Technology (Group) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Shanghai Obio Technology (Group) is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shanghai Obio Technology (Group) is the large dot.

Shanghai Obio Technology (Group) competitors and peer comparison

How Shanghai Obio Technology (Group) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shanghai Obio Technology (Group) against its 20 peers (data as of 6 Nov 2026)
Measure	688238.SS	Peer median	Rank in peer set
1-month return	-21.4%	-13.2%	6th lowest of 21
6-month return	-4.4%	-7.3%	8th highest of 20
Distance from 52-week high	-30.4%	-35.3%	8th highest of 21
Revenue growth (TTM)	+20.1%	+3.6%	4th highest of 16
Operating margin	-78.9%	-9.8%	3rd lowest of 16
EV / Sales	11.4×	10.7×	8th most expensive of 16
ROIC minus cost of capital	-16.9 pp	-9.3 pp	5th lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Shanghai Obio Technology (Group) 688238.SS	China	$462M	-4%	+20%	-79%	11.4×	n/a	n/a
Shattuck Labs STTK	United States	$464M	-33%	-67%	-5,571%	258.1×	n/a	n/a
Komipharm International 041960.KS	South Korea	$460M	-12%	-3%	2%	12.1×	n/a	n/a
Eupraxia Pharmaceuticals EPRX.TO	Canada	$466M	-5%	n/a	n/a	n/a	n/a	n/a
Steminent Biotherapeutics 7729.TWO	Taiwan	$458M	+139%	n/a	n/a	n/a	n/a	n/a
Medigen Vaccine Biologics 6547.TWO	Taiwan	$467M	-5%	+44%	10%	18.0×	n/a	n/a
Jacobio Pharmaceuticals 1167.HK	Hong Kong	$468M	-27%	+286%	68%	2.5×	-14.9%	-36.1%
Shanghai ZJ Bio-Tech 688317.SS	China	$468M	-16%	-18%	-75%	5.2×	6.0%	-62.3%
Hanx Biopharmaceuticals (Wuhan) 3378.HK	Hong Kong	$469M	-13%	n/a	n/a	n/a	n/a	n/a
TaiMed Biologics 4147.TWO	Taiwan	$454M	+10%	+4%	-30%	22.4×	31.8%	-3.3%
Qingdao Vland Biotech 603739.SS	China	$450M	-21%	+5%	7%	2.3×	18.2%	+7.3%
Monopar Therapeutics MNPR	United States	$479M	+12%	n/a	n/a	n/a	n/a	n/a
CHO Pharma 6586.TWO	Taiwan	$480M	+57%	-47%	-17,694%	8,168.1×	n/a	n/a
Shanghai Shen Lian Biomedical 688098.SS	China	$444M	-18%	-17%	-16%	12.1×	n/a	n/a
Wuhan Hiteck Biological Pharma 300683.SZ	China	$443M	-36%	-30%	-27%	5.9×	n/a	n/a
Scinopharm Taiwan 1789.TW	Taiwan	$482M	-1%	-5%	-4%	5.2×	15.2%	+0.5%
TenNor Therapeutics Suzhou 6872.HK	Hong Kong	$440M	n/a	n/a	n/a	n/a	n/a	n/a
Ever Supreme Bio Technology 6712.TWO	Taiwan	$439M	+9%	+13%	47%	12.7×	5.8%	+70.5%
Hubei Goto Biopharm 300966.SZ	China	$427M	-7%	+6%	-10%	6.4×	n/a	n/a
EirGenix 6589.TW	Taiwan	$427M	+2%	+27%	-71%	10.7×	n/a	n/a
Polynovo PNV.AX	Australia	$426M	-12%	+13%	5%	4.2×	53.3%	+37.6%

Questions

Which companies are Shanghai Obio Technology (Group)'s closest peers?: The cockpit's peer set: Shattuck Labs (STTK), Komipharm International (041960.KS), Eupraxia Pharmaceuticals (EPRX.TO), Steminent Biotherapeutics (7729.TWO), Medigen Vaccine Biologics (6547.TWO), Jacobio Pharmaceuticals (1167.HK), Shanghai ZJ Bio-Tech (688317.SS), Hanx Biopharmaceuticals (Wuhan) (3378.HK).
Is Shanghai Obio Technology (Group) expensive compared with its peers?: On ev / sales it trades at 11.4× against a peer median of 10.7×, 8th most expensive of 16 in its peer set.
How has Shanghai Obio Technology (Group) stock performed?: Over six months to 6 Nov 2026 the shares returned -4.4% against -7.3% for the median peer; over one year -13.3%.